 |
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2010, vol. 16, book 3
Subject Collection: Medicine
Page: 70 - 73
DOI: 10.5272/jimab.1632010_70
Online date: March 18, 2011
OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
Deyan Davidov,
Department of Chemotherapy, Oncological Center, Medical University, Pleven, Bulgaria
ABSTRACT:
Objectives: Single agent intravenous Topotecan is an effective treatment for small cell lung cancer /SCLC/ after failure of first- line chemotherapy. The aim of this study was to evaluate the efficacy and toxicity of intravenous Topotecan in recurrent SCCC. Methods: In the period 2008- 2009 seventeen consecutive patients with relapsed SCLC entered the study. The treatment schedule consists of Topotecan 1,5 mg/m2 i.v. for five consecutive days, with repetition every 21 days. Results: Overall response rate was 23,5%. Median survival was 6,4 months. Nausea, vomiting and neutropenia were most common side effects. Conclusion: Intravenous Topotecan is effective as second- line therapy for patients with relapsed SCCC with good tolerability.
Key words: Relapsed small cell lung cancer, Second- line treatment, Intravenous Topotecan, Survival.
Page: 70-73; FULL TEXT PDF (108 KB) Abstract
REFERENCES:
1. Jemal A, Siegel R, Ward E et al, Cancer Statistics, 2006. CA Cancer J Clin 2006; 56: 106- 130 [CrossRef] http://dx.doi.org/10.3322/canjclin.56.2.106
2. Feld R, Ginsberg RJ, Rayne DG et al, Lung. In: Abeloff MD, Armitage JO, Lichter AS et al., eds. Clinical Oncology, New York: Churchill Livingstone, Inc., 1995: 1118- 1141
3. Rosti G, Bevilacqua G, Bidoli P et al, Small cell lung cancer, Ann Oncol, 2006; 17: /suppl 2/, ii5- ii10 [CrossRef] http://dx.doi.org/10.1093/annonc/mdj910
4. Carney DN, Shepherd FA, Treatment of SCLC: chemotherapy. In: Hansen NN, ed. Textbook of lung cancer. London, Martin Dunitz Ltd, 2000; 261- 272
5. Murren J, Clatstein E, Pass H et al, Small cell lung cancer. In: De Vita VT, Hellman S, Rosenberg S, eds. Cancer: Principles and practice in oncology. Philadelphia, Lippincott, Williams and Wilkins, 2001, 983- 1018
6. Giaccone G, Splinter T, Debruyne C et al, Randomized study of paclitaxel- cisplatin versus cisplatin- teniposide in patients with advanced non- small- cell lung cancer, J Clin Oncol, 1998; 16: 2133- 2141 [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/9626213
7. Takimoto C, Abruck S, Campothecins, In: Chabner B, Long D, eds. Cancer chemotherapy and Biotherapy, Second edition, Philadelphia, Lippincott- Raven, 1996; 463- 484
8. Ardizoni A, Hansen H, Dombernowsky P et al, Topotecan, a new active drug in second- line treatment of small cell lung cancer: a phase II study in patients with refractory and sensitive disease, J Clin Oncol, 1997; May 15(5):2090-2096 [PubMed]
9. Von Pavel J, Schiller J, Shepherd FA et al, Topotecan versus cyclophosphamide, doxorubicin, and vincristin for the treatment of recurrent small-cell lung cancer, J Clin Oncol 1999 Feb; 17(2): 658- 667 [PubMed]
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; Jan 1;47(1):207-14. [PubMed]
11. Brimdage MD, Pater JL, Zee B, Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 1993 Jul 21;85(14):1138-48. [PubMed]
12. Kaplan EL, Meyer P, Non-parametric estimation from incomplete observations. J Am Stat Assoc, 1959; 53; 457- 481
13. Huisman C, Postmus PE, Giaccone G, Smit EF. Second-line chemotherapy and its evaluation in small cell lung cancer, Cancer Treat Rev, 1999, Aug;25(4):199- 206 [CrossRef] [PubMed]
14. Von Pavel J, Gatzemeier U, Pujol Jl et al, Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small- cell lung cancer, J Clin Oncol 2001; Mar 15;19(6): 1743- 1749 [PubMed]